There is no list price for sermorelin, because there is no manufacturer. Understanding why is the key to reading every quote you will get — and to spotting the programs that are pricing the consult rather than the drug.
Why pricing works the way it does
Sermorelin’s FDA-approved brand product, Geref, left the market in 2008. The withdrawal was commercial: recombinant HGH had taken over the indication and the product was not worth maintaining. No safety finding, no efficacy failure.
The practical consequence is that every sermorelin product in the United States today is a compounded preparation. Compounded pricing is not set by a manufacturer. It is set by whichever 503A pharmacy prepares it and whichever clinical program contracts with that pharmacy. That is why quotes vary so widely and why comparing headline monthly numbers is close to meaningless without unpacking them.
Ignore the monthly number. Ask four questions instead: (1) What is the total milligram quantity dispensed? (2) Are baseline labs included or billed separately? (3) Does the price include follow-up consults or only the initial? (4) Which pharmacy fills it?
Two programs with identical monthly prices can differ by a factor of two on drug quantity.
What you are actually paying for
| Cost component | What it covers | Where it hides |
|---|---|---|
| Initial consultation | Clinician evaluation, intake, prescribing decision | Sometimes free as a loss leader, recovered in drug margin |
| Baseline labs | IGF-1, metabolic panel, often hormone panel | Frequently excluded from the advertised price |
| The compounded preparation | Pharmacy compounding, vial, shipping | Varies by concentration and vial size |
| Follow-up / monitoring | Repeat labs, dose adjustment, refills | Often billed separately after month one |
| Supplies | Bacteriostatic water, syringes, sharps disposal | Usually not included |
Insurance: assume no
Compounded preparations of substances without a current FDA-approved indication are generally not covered. Sermorelin has no live approval to bill against. A small number of people successfully submit for partial reimbursement of the labs, not the drug. Budget as cash pay and treat anything else as a bonus.
The maintenance question
GH secretagogue protocols are not one-and-done. Whatever effect you get is downstream of ongoing stimulation, and it recedes when stimulation stops. That means the number that matters is not the first month — it is twelve months, or twenty-four, at the program’s ongoing rate including follow-up labs.
Run that math before the first consult, not after the third refill.
The research-channel comparison, stated honestly
Research-grade material is dramatically cheaper. It is also a categorically different purchase: sold for laboratory use only and not for human consumption, with no clinician evaluating you, no pharmacy compounding to a standard, no monitoring, and purity that depends entirely on whether the supplier publishes lot-specific third-party testing.
People make that trade knowingly all the time. The failure mode is making it unknowingly — assuming the cheaper vial is the same product at a better price. It is not the same product.
Prescription pathway with clinician evaluation
Frequently Asked
Because there is no brand. Geref was discontinued in 2008 for commercial reasons. Every sermorelin product available today is compounded, so pricing is set by individual pharmacies and the programs that contract with them rather than by a manufacturer list price.
Almost never. Compounded preparations of unapproved substances are generally not covered, and sermorelin has no current FDA-approved indication to bill against. Assume cash pay.
Four things: the consult and follow-up structure, whether labs are included, the pharmacy the program contracts with, and vial size or concentration. Two programs quoting different monthly numbers are often not selling the same amount of drug.
Substantially, and it is a different product category entirely — sold for laboratory use, not for human consumption, with no clinician, no pharmacy oversight, and quality that varies by supplier and batch.
Not obviously. Compounded pricing is driven by pharmacy costs and program margins, neither of which is under downward pressure. The July 2026 PCAC votes could eventually expand the compoundable list, but that affects different compounds and runs on a multi-year timeline.